New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.93
5.42
+1.91%
Follow ABBV
Alert me
Analysts’ price targets Wall Street, collected weekly
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Sep ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 25,638 | 28,216 | 32,753 | 33,266 | 45,804 | 56,197 | 58,054 | 54,318 | 56,334 | 61,160 | 66,014 | +10.1% | 67,798 | 73,945 | 79,776 | +9.3% | |
| Gross margin, % | 77.25 | 75.04 | 76.44 | 77.64 | 66.41 | 68.96 | 70.00 | 62.42 | 69.99 | 70.24 | 73.72 | (7.0) pt | ||||||
| EBT | 7,884 | 7,727 | 5,197 | 8,426 | 3,398 | 12,989 | 13,477 | 6,250 | 3,716 | 6,597 | 12,814 | (2.0%) | ||||||
| EBT margin, % | 30.75 | 27.39 | 15.87 | 25.33 | 7.42 | 23.11 | 23.21 | 11.51 | 6.60 | 10.79 | 19.41 | (20.0) pt | ||||||
| Net income | 5,953 | 5,309 | 5,687 | 7,882 | 4,622 | 11,549 | 11,845 | 4,873 | 4,286 | 4,233 | 10,348 | (3.7%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 15.81 | 17.68 | 21.25 | 22.46 | 27.48 | 31.75 | 32.78 | 30.72 | 31.85 | 34.57 | 37.32 | +9.1% | |||||
| Earnings | 3.63 | 3.30 | 3.66 | 5.28 | 2.72 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | 5.81 | (4.7%) | ||||||
| Cash flow | 4.34 | 6.24 | 8.71 | 9.00 | 10.55 | 12.87 | 14.08 | 12.92 | 10.63 | 10.76 | 11.36 | +10.6% | ||||||
| Capex | (0.30) | (0.33) | (0.41) | (0.37) | (0.48) | (0.44) | (0.39) | (0.44) | (0.55) | (0.69) | (0.69) | +9.8% | ||||||
| Free cash flow | 4.05 | 5.91 | 8.30 | 8.62 | 10.07 | 12.42 | 13.69 | 12.48 | 10.08 | 10.07 | 10.67 | +10.7% | ||||||
| Book value | 2.86 | 3.19 | (5.48) | (5.52) | 7.86 | 8.72 | 9.76 | 5.88 | 1.90 | (1.82) | (2.57) | n/m | ||||||
| Shares, m | 1,622 | 1,596 | 1,541 | 1,481 | 1,667 | 1,770 | 1,771 | 1,768 | 1,769 | 1,769 | 1,769 | +1.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 17.19 | 29.91 | 25.75 | 16.77 | 37.47 | 20.99 | 24.57 | 58.54 | 74.04 | 96.82 | 48.80 | 40.2 | |||||
| P/S | 3.95 | 5.57 | 4.34 | 3.94 | 3.90 | 4.26 | 4.95 | 5.20 | 5.58 | 6.61 | 7.60 | 4.8 | ||||||
| P/B | 21.84 | 30.81 | 0.00 | 0.00 | 13.64 | 15.53 | 16.64 | 27.18 | 93.45 | 0.00 | 0.00 | 21.9 | ||||||
| EV/Sales | 5.13 | 6.54 | 5.32 | 4.75 | 5.59 | 5.45 | 5.88 | 6.06 | 6.67 | 7.63 | 8.66 | 5.9 | ||||||
| EV/FCF | 20.06 | 19.58 | 13.63 | 12.37 | 15.26 | 13.94 | 14.09 | 14.92 | 21.08 | 26.18 | 30.29 | 17.1 | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 7,041 | 9,960 | 13,427 | 13,324 | 17,588 | 22,777 | 24,943 | 22,839 | 18,806 | 19,030 | 20,089 | +11.7% | |||||
| Capex | (479) | (529) | (638) | (552) | (798) | (787) | (695) | (777) | (974) | (1,214) | (1,217) | +10.9% | ||||||
| Free cash flow | 6,562 | 9,431 | 12,789 | 12,772 | 16,790 | 21,990 | 24,248 | 22,062 | 17,832 | 17,816 | 18,872 | +11.7% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 6,406 | 4,582 | (294) | 33,934 | (4,488) | (7,266) | (1,075) | (4,839) | (13,167) | (14,227) | (5,622) | n/m | |||||
| Net debt | 30,419 | 27,579 | 32,249 | 26,804 | 77,577 | 66,854 | 54,042 | 46,569 | 61,589 | 62,239 | 70,129 | +8.3% | ||||||
| Shareholders’ equity | 4,636 | 5,097 | (8,446) | (8,172) | 13,097 | 15,436 | 17,287 | 10,397 | 3,364 | (3,228) | (4,538) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | 9.99 | 7.76 | 8.74 | 10.62 | 3.85 | 7.77 | 8.26 | 3.52 | 3.14 | 3.11 | 7.32 | (6.9) pt | |||||
| ROIC | 16.65 | 18.26 | 16.76 | 43.55 | 7.83 | 13.61 | 15.87 | 14.00 | 8.79 | 15.97 | 20.23 | (0.7) pt | ||||||
| ROE | 138.75 | 109.09 | (339.62) | (94.86) | 187.45 | 80.90 | 72.01 | 34.82 | 61.59 | 6,155.88 | (288.69) | +6,017.1 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 30,000 | 29,000 | 30,000 | 30,000 | 47,000 | 50,000 | 50,000 | 50,000 | 55,000 | 57,000 | — | +7.4% | |||||
| Revenue/emp, $m | 0.85 | 0.97 | 1.09 | 1.11 | 0.97 | 1.12 | 1.16 | 1.09 | 1.02 | 1.07 | — | +2.6% | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated Nov 18, 2026
Business profile
Where the money comes from and where it goes Fiscal 2025
| Skyrizi | 17,562 | 28.71% |
|---|---|---|
| Rinvoq | 8,304 | 13.58% |
| Humira | 4,540 | 7.42% |
| Botox Therapeutic | 3,769 | 6.16% |
| Vraylar | 3,621 | 5.92% |
| Imbruvica | 2,869 | 4.69% |
| Venclexta | 2,792 | 4.57% |
| All other | 2,627 | 4.30% |
| Botox Cosmetic | 2,602 | 4.25% |
| Other, not broken out | 1,545 | 2.53% |
| Mavyret | 1,317 | 2.15% |
| Ubrelvy | 1,271 | 2.08% |
| Other Aesthetics | 1,265 | 2.07% |
| Qulipta | 1,036 | 1.69% |
| Other Eye Care | 1,009 | 1.65% |
| Juvederm Collection | 993 | 1.62% |
| Linzess | 907 | 1.48% |
| Elahere | 690 | 1.13% |
| Ozurdex | 493 | 0.81% |
| Vyalev | 482 | 0.79% |
| Lumigan/Ganfort | 410 | 0.67% |
| Duodopa | 381 | 0.62% |
| Epkinly | 271 | 0.44% |
| Other Neuroscience | 207 | 0.34% |
| Alphagan/Combigan | 197 | 0.32% |
| Gross margin | 70.24% | |
| Operating margin | 24.65% | |
| Pre-tax margin | 10.79% |
AbbVie Inc. vs peers in Drug Manufacturers General (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | $1.27T | 43.9× | 42.2× FY26e | +38.61% (above 0%: growing) | +16.26% (above 0%: growing) | +21.80% (above 0%: growing) | 83.88% | 36.52% | Compare |
| JNJ Johnson & Johnson | $650.7B | 40.5× | 41.8× FY26e | +5.86% (above 0%: growing) | −95.75% (below 0%: shrinking) | −21.44% (below 0%: shrinking) | 68.12% | 1.72% | Compare |
| ABBV AbbVie Inc. | $501.2B | 48.8× | 37.6× FY26e | +10.32% (above 0%: growing) | +2,270.00% (above 0%: growing) | +9.97% (above 0%: growing) | 75.38% | 36.01% | |
| MRK Merck & Co., Inc. | $328.6B | 137× | 105× FY26e | +4.68% (above 0%: growing) | −12.07% (below 0%: shrinking) | −19.27% (below 0%: shrinking) | 72.95% | 31.90% | Compare |
| NVS Novartis AG | $277.7B | 28.8× | 24.0× FY26e | +4.67% (above 0%: growing) | −68.81% (below 0%: shrinking) | −17.81% (below 0%: shrinking) | 75.99% | 12.26% | Compare |
| AZN AstraZeneca PLC | $272.1B | 24.6× | 24.2× FY26e | +6.70% (above 0%: growing) | +23.46% (above 0%: growing) | +1.99% (above 0%: growing) | 81.82% | 27.07% | Compare |
| AMGN Amgen Inc. | $237.4B | 25.2× | 24.0× FY26e | +8.45% (above 0%: growing) | +19.39% (above 0%: growing) | −13.98% (below 0%: shrinking) | 73.10% | 35.79% | Compare |
| GILD Gilead Sciences, Inc. | $207.8B | — (loss-making) | — (loss-making) | +6.83% (above 0%: growing) | −20.16% (below 0%: shrinking) | +21.13% (above 0%: growing) | 81.07% | 41.71% | Compare |
| PFE Pfizer Inc. | $158.2B | 38.8× | 18.7× FY26e | −0.43% (below 0%: shrinking) | −9.68% (below 0%: shrinking) | +20.02% (above 0%: growing) | 75.71% | 22.14% | Compare |
| Median of peers | $274.9B | 38.8× | 24.2× | +6.28% | −10.87% | −5.99% | 75.85% | 29.49% |
From the latest earnings call
- CEO Rob Michael said AbbVie received U.S. approval for a Skyrizi dosing option in Crohn’s disease and is testing combinations with other mechanisms.
- Chief Commercial Officer Jeff Stewart said Juvemo’s initial demand exceeded expectations, although patients were using enrollment and medical exception processes while access was unavailable.
Largest institutional holders 13F, quarter to Jun 30, 2026
Held by institutions
75.36%
Held by the ten largest
38.95%
| Holder | Shares | Stake | Change |
|---|---|---|---|
| Vanguard | 182.90m | 10.35% | −386.32k |
| BlackRock | 149.49m | 8.46% | −1.21m |
| State Street | 82.60m | 4.67% | +1.38m |
| Capital Group | 65.57m | 3.71% | +3.41m |
| JPMorgan Chase | 47.86m | 2.71% | −8.88m |
| Geode Capital Management | 47.00m | 2.66% | +260.85k |
| Morgan Stanley | 38.90m | 2.20% | +884.23k |
| UBS | 27.11m | 1.53% | −1.10m |
| Norges Bank | 25.55m | 1.45% | +25.55m |
| Bank of America | 21.24m | 1.20% | −2.70m |
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.
AbbVie Inc. (ABBV) Latest News
What happened
- Deal AbbVie agreed to pay DISCO Pharmaceuticals $40 million upfront and up to $2.5 billion in milestones, plus tiered royalties, for a solid-tumor therapeutics collaboration.
- Results AbbVie reported third-quarter revenue of about $17.4 billion, raised its 2026 outlook to about $67.8 billion and increased its dividend.
- Product AbbVie reported Phase 3 TEMPLE results showing QULIPTA was more effective and better tolerated than topiramate for migraine prevention.
- Deal AbbVie agreed to license Nxera Pharma’s oral EP4 agonist for inflammatory bowel disease in a deal worth up to $1.37 billion.
- AbbVie (ABBV) Stock Climbs As Q3 Earnings Fuel Growth Case Simply Wall St.
- ABBV Q3 deep dive: Immunology and neuroscience drive growth, pipeline progress continues StockStory
- ABBV Q3 Earnings Call Highlights Raised Outlook and Pipeline Progress Zacks
- AbbVie (ABBV) Q3 2026 Earnings Call Transcript The Motley Fool transcript
- AbbVie (ABBV) Stock Still Looks Cheap On Its 197% Five Year Run Simply Wall St.
- AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000 24/7 Wall St.
- Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” Milestone TIKR
- AbbVie’s Pipeline Had a Mixed Week. The October 30 Report Has to Show Its Guidance Still Rises TIKR
- AbbVie TEMPLE Study Demonstrates Superior Tolerability and Efficacy of Atogepant (QULIPTA®) in Head-to-Head Migraine Prevention Trial CNW Group
- AbbVie (ABBV) Seeks FDA Approval For Etentamig In Multiple Myeloma Simply Wall St.
13 more headlines
- AbbVie Is Near Its High. Piper Sandler Sees Another 23% TIKR
- The One Thing To Settle Before Buying AbbVie Stock Trefis +1 report
- Prediction: AbbVie's Next Blockbuster Is Hiding in a Two-Drug Crohn's Combo The Motley Fool
- AbbVie Stock Hits a Record After a 5.2% Dividend Raise: Why Its 276% Payout Ratio Doesn’t Tell the Entire Story TIKR
- AbbVie: 3 Key Takeaways for Long-Term Investors The Motley Fool
- What AbbVie (ABBV) Said on Its Q3 Earnings Call MarketBeat transcript
- AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views MT Newswires
- ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View Zacks
- AbbVie (NYSE:ABBV) posts Q3 2026 sales in line with estimates StockStory
- AbbVie Is Up 10% in a Month to a 52-Week High: Is There “More Room for Multiple Expansion”? TIKR
- AbbVie Reports Third-Quarter 2026 Financial Results PR Newswire
- Glaukos Soars 26% on “Exceptional” Quarter and $1 Billion 2027 Sales Outlook TIKR
- AbbVie (ABBV) reports earnings tomorrow: what to expect StockStory
ABBV metrics, ten years each
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
AbbVie is a research-based biopharmaceutical company that develops, manufactures and sells medicines and therapies around the world. It was founded in 2012, is headquartered in North Chicago and is led by Chief Executive Officer Robert A. Michael. Its business operates as a single global segment.
Its medicines span immunology, neuroscience, oncology and eye care. Immunology treatments include Skyrizi, Rinvoq and Humira, which are used for autoimmune and inflammatory conditions. Skyrizi is an injected biologic, while Rinvoq is an oral medicine. The approved uses and available products vary by market.